#USA #Conshohocken #Tiger Aesthetics #Bioderma #BioBody

Tiger Aesthetics Introduces New Divisions for Enhanced Sales Growth

In a strategic move to bolster its presence in the medical aesthetics market, Tiger Aesthetics Medical has announced the formation of two dedicated divisions: BioBody™ and BioDerma™. This reorganization is designed to optimize sales efforts and improve market penetration, as the company anticipates rapid growth in demand for its innovative aesthetic products.

The launch of these divisions comes alongside significant investments in the sales force, additional focused marketing programs, and upgrades to infrastructure that will facilitate Tiger’s expansion across core channels in Medical Aesthetics. This pivot is timely, as the company prepares to launch its new product, dermaClae™, designed for facial and hand rejuvenation in early 2027, alongside the already established alloClae™, which is used for breast and body contouring.

Purpose of the New Divisions

The BioBody™ division will cater specifically to board-certified plastic and cosmetic surgeons, while the BioDerma™ division will focus on dermatologists and MedSpas. Each division will be supported by dedicated commercial leadership teams to ensure they address the specific needs of their markets effectively. As both divisions are anticipated to grow rapidly, the aim is to expand the workforce to over 100 sales representatives by the end of 2026, with plans to double this number in the following years.

Caro Van Hove, President of Tiger Aesthetics, remarked, “The creation of BioBody™ and BioDerma™ represents a pivotal moment in our growth strategy. By having these two focused divisions, we can provide providers with the dedicated resources needed to meet the substantial demand for alloClae™ while preparing for the forthcoming launch of dermaClae™.”

Leadership Decisions

To lead the BioDerma™ division, Stephen Stafford, a seasoned commercial leader, will spearhead efforts to reinforce Tiger’s standing with dermatologists and MedSpas. He highlighted the tremendous opportunities that lie ahead, especially with both alloClae™ experiencing rapid market acceptance and the new dermaClae™ launch approaching. Stafford emphasized the importance of building a robust sales team that is equipped to navigate the nuances of these specific channels effectively.

Long-term Vision and Goals

With this strategic move, Tiger Aesthetics aims to significantly increase its market share in the Medical Aesthetics field. The focused nature of the two new divisions will enable the company to better address the unique demands of its diverse clientele, driving significant market penetration with a comprehensive range of its products related to regenerative aesthetics, including its successful offerings in breast, face, and body aesthetics.

Tiger Aesthetics, recognized for its commitment to innovation in regenerative aesthetics, emphasizes their foundation in advanced tissue engineering. Their flagship products, alloClae™ and the soon-to-be-released dermaClae™, are at the forefront of the market, aimed at delivering natural, non-surgical aesthetic solutions. Beyond the adipose tissue products, Tiger also offers an extensive portfolio of supporting medical devices, reinforcing its position as a leader in the field.

Tiger Aesthetics encourages those interested in learning more about its divisions or considering sales positions to visit their LinkedIn page or their websites at tiger-aesthetics.com and tigerbioderma.com.

About Tiger Aesthetics Medical

Headquartered in Conshohocken, PA, Tiger Aesthetics Medical is committed to revolutionizing the regenerative aesthetics landscape, supported by robust R&D and a passion for providing high-quality tissue products. The company is grateful to the donors and families contributing to its mission and is dedicated to utilizing tissue across various applications to honor the trust placed in them. Visit their website for further information about their innovations and commitment to the field.